產(chǎn)品屬性：
產(chǎn)品名稱 | ELOVL1-IN-1 |
規(guī)格 | 5 mg、10 mg |
貨號(hào) | EY-01Y18075 |
Cas No.: 2227482-41-7
別名: N/A
化學(xué)名: N/A
分子式: C18H14F2N4O
分子量: 340.33
溶解度: N/A
儲(chǔ)存條件: Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1].ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1].ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1].[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1.
特別提醒公司產(chǎn)品僅供科研使用
